ReviewJournal of clinical medicine2024
Transcatheter Tricuspid Regurgitation Repair-An Overview of Techniques and Eligible Patient Selection.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Response in renal function after transcatheter tricuspid edge-to-edge repair.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Critically Evaluating TriClip Edge-to-Edge Repair for Severe Tricuspid Regurgitation with Large Coaptation Gaps: Limitations of a Nine-Patient Retrospective Study and Evidence-Based Recommendations for Patient Selection and Future Trials.Cardiovascular drugs and therapy · 2026Article
- Response To: 'Critically Evaluating TriClip Edge-to-Edge Repair for Severe Tricuspid Regurgitation with Large Coaptation Gaps: Limitations of a Nine Patient Retrospective Study and Evidence Based Recommendations for Patient Selection and Future Trials.Cardiovascular drugs and therapy · 2026Article
- Right Ventricular Dynamics in Tricuspid Regurgitation: Insights into Reverse Remodeling and Outcome Prediction Post Transcatheter Valve Intervention.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tricuspid regurgitation (TR) is frequently encountered in clinical practice. It is classified into primary TR (organic), which accounts for a minority of cases; and into secondary TR (functional), which has a higher prevalence. Although it can be asymptomatic for a long time, TR causes right ventricle dysfunction and increases hospitalizations for heart failure and mortality. In most patients with severe, isolated TR, surgery is not indicated due to the high surgical risk. In the last 10 years, transcatheter tricuspid valve repair became feasible with the following good results: reduction in TR severity, reverse remodeling of the right heart chambers, improvement in symptoms and reduction in hospitalization time. This paper presents the main transcatheter techniques and data from relevant trials that used these techniques, focusing on patient characteristics that define eligibility and high probability of repair. Information is provided regarding the observed benefits and the complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.